Tag - PRVB

Markets

Cantor ups Provention Bio PT on FDA T1D approval

Cantor Fitzgerald raised its price target for Provention Bio (NASDAQ:PRVB) to $16 from $12 and maintained an “overweight” rating after the FDA approved teplizumab (brand name, TZIELD) to delay the onset of Type 1...

November 18, 2022

Developments

Provention Bio gets FDA breakthrough therapy designation for PRV-031

Provention Bio (NASDAQ:PRVB) received breakthrough therapy designation for PRV-031 for the prevention or delay of Type 1 diabetes (T1D) in at-risk individuals. PRV-031, an anti-CD3 monoclonal antibody also known as...

August 6, 2019

Developments

Provention Bio begins Phase 3 trial of teplizumab for recent onset Type 1 diabetes

Provention Bio (NASDAQ:PRVB) has dosed the first patient in its Phase 3 clinical trial of teplizumab for Type 1 diabetes (T1D). The trial will determine whether teplizumab, an anti-CD3 monoclonal antibody, slows the...

April 9, 2019

Tag - PRVB

Cantor ups Provention Bio PT on FDA T1D approval

Provention Bio gets FDA breakthrough therapy designation for PRV-031

Provention Bio begins Phase 3 trial of teplizumab for recent onset Type 1 diabetes

General

More